Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Boehringer Ingelheim
Mallinckrodt
AstraZeneca
McKesson

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

Litigation Details for Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)


Email this page to a colleague

« Back to Dashboard

Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)

Docket ⤷  Free Forever Trial Date Filed 2015-03-17
Court District Court, N.D. California Date Terminated 2017-08-23
Cause 28:1338 Patent Infringement Assigned To Beth Labson Freeman
Jury Demand Both Referred To Nathanael M. Cousins
Parties GENENTECH INC
Patents 10,029,011; 7,811,572; 8,080,534; 8,383,122; 8,394,780; 8,461,101; 8,633,149; 8,653,021; 9,023,001
Attorneys Aldo Noto
Firms Davis Wright and Tremaine
Link to Docket External link to docket
Biologic Drugs cited in Phigenix, Inc. v. Genentech, Inc.

Details for Phigenix, Inc. v. Genentech, Inc. (N.D. Cal. 2015)

Date Filed Document No. Description Snippet Link To Document
2016-08-08 234 Order ORDER CONSTRUING CLAIMS IN U.S. PATENT NO. 8,080,534. Signed by Judge Beth Labson Freeman on 8/… U.S. PATENT NO. 8,080,534 …infringement of U.S. Patent No. 8,080,534B2 21 (“the ’534 Patent”). The Court…the ’534 Patent. 23 I. BACKGROUND ON THE ’534 PATENT …It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the External link to document
2016-09-22 257 ) cell lines. (See, e.g., id., 10:29-11:18.) The '534 14 patent includes separate claims directed…asserted claims 1, 2, and 8 of U.S. Patent No. 8,080,534 (the “'534 patent”) under 6 35 U.S.C. § 112…of the '534 patent are invalid as a matter of law because the 12 '534 patent’s specification… genes. ('534 17 patent (ECF No. 21-1), 6:22-23.) The '534 patent purports to disclose the…disclosed in 13 the parent patent application. See Manual of Patent Examining Procedure § 201.08 ( External link to document
2016-10-31 290 Order on Motion for Sanctions infringement of U.S. Patent No. 8,080,534 17 (“the ’534 patent”). ECF 21. …expression and thus infringes the ’534 patent. Id. Claim 1 of the ’534 patent is …Plaintiff Phigenix, Inc. (“Phigenix”) brings this patent infringement lawsuit against … 23 claims 1, 2, and 8 of the ’534 patent. ECF 21. Kadcyla comprises the antibody trastuzumab… to its 4 patent portfolio, and informed Genentech of its theory External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKinsey
Johnson and Johnson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.